All In Biotech

Drug Trial Radar · NCT06109272

A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

A Phase 2/3, Randomized Study to Evaluate the Dose Optimization, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab in Subjects With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Who Have Not Previously Received Systemic Treatment

Last checked: Nov 20, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

89

Actual

Start

Jan 11, 2024

Primary completion

Jan 2027

Study completion Jan 2027

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Oct 31, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Hepatocellular carcinoma (HCC) is a common cancer worldwide and a leading cause of cancer-related death. The majority of participants first presenting with HCC have advanced unresectable or metastatic disease. The purpose of this study is to evaluate the optimized dose, adverse events, and efficacy of livmoniplimab in combination with budigalimab. Livmoniplimab is an investigational drug being developed for the treatment of HCC. There are 2 stages to this study. In Stage 1, there are 3 treatment arms and participants will be randomized in a 1:1:1 ratio. Participants will either receive livmoniplimab (at different doses) in combination with budigalimab (another investigational drug), atezolizumab in combination with bevacizumab, or tremelimumab in combination with durvalumab. In Stage 2, there are 2 treatments arms and participants will be randomized in a 1:1 ratio. Participants will either receive livmoniplimab (optimized dose) in combination with budigalimab or tremelimumab in combination with durvalumab. Approximately 660 adult participants will be enrolled in the study across 185 sites worldwide. Stage 1: In arm 1, participants will receive intravenously (IV) infused livmoniplimab (Dose 1) in combination with IV infused budigalimab, every 3 weeks. In arm 2, participants will receive IV infused livmoniplimab (Dose 2) in combination with IV infused budigalimab, every 3 weeks. In Arm 3 (control), participants will receive the investigator's choice: IV atezolizumab in combination with IV bevacizumab every 3 weeks or single dose IV tremelimumab in combination with IV durvalumab every 4 weeks. Stage 2: In arm 1, participants will receive IV infused livmoniplimab (optimized dose) in combination with IV infused budigalimab, every 3 weeks. In Arm 2 (control), participants will receive single dose IV tremelimumab in combination with IV durvalumab every 4 weeks. All participants will continue treatment until disease progression or discontinuation criteria are met, whichever occurs first. The estimated duration of this study is about 56 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, questionnaires, and scans.

Conditions

  • Hepatocellular Carcinoma

Interventions

  • LivmoniplimabDrug

    Intravenous (IV) Solution

  • BudigalimabDrug

    Intravenous (IV) Solution

  • DurvalumabDrug

    Intravenous (IV) Solution

  • AtezolizumabDrug

    Intravenous (IV) Solution

  • BevacizumabDrug

    Intravenous (IV) Solution

  • TremelimumabDrug

    Intravenous (IV) Solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Stage 1: Best Overall Response (BOR) per InvestigatorTime frame: Through Study Completion, Up to Approximately 56 Months
  2. Stage 2: Overall Survival (OS)Time frame: Through Study Completion, Up to Approximately 56 Months

Locations

37 sites in 6 countries. Site status is shown where the registry gives one.

  • City of Hope /ID# 261468

    Duarte, California

  • City of Hope - Orange County Lennar Foundation Cancer Center /ID# 261669

    Irvine, California

  • UC Irvine /ID# 255673

    Orange, California

  • The University of Chicago Medical Center /ID# 255674

    Chicago, Illinois

  • Alliance for Multispecialty Research LLC Kansas City Oncology /ID# 256830

    Merriam, Kansas

  • Norton Cancer Institute /ID# 260775

    Louisville, Kentucky

  • Henry Ford Hospital - Detroit /ID# 255803

    Detroit, Michigan

  • Metro Minnesota Community Oncology Research Consortium (MMCORC) /ID# 256041

    Saint Louis Park, Minnesota

  • Washington University-School of Medicine /ID# 255720

    St Louis, Missouri

  • Texas Oncology - Abilene - Antilley Road /ID# 265820

    Abilene, Texas

  • Texas Oncology - Dallas - Worth Street /ID# 265806

    Dallas, Texas

  • Baylor Scott and White Research Institute /ID# 260853

    Dallas, Texas

  • Oncology and Hematology Associates of Southwest Virginia /ID# 265834

    Roanoke, Virginia

  • Hopital Avicenne /ID# 266005

    Bobigny, Île-de-France Region, France

  • Hopital Beaujon /ID# 256551

    Clichy, Île-de-France Region, France

  • CHU Grenoble - Hopital Michallon /ID# 256627

    La Tronche, Isere, France

  • Institut Gustave Roussy /ID# 258460

    Villejuif, Val-de-Marne, France

  • IRCCS AOU di Bologna Policlinico Sant Orsola Malpighi /ID# 256412

    Bologna, Italy

  • Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone /ID# 256681

    Palermo, Italy

  • Fondazione Policlinico Universitario Campus Bio-Medico /ID# 256895

    Roma, Italy

  • IRCCS Istituto Clinico Humanitas /ID# 256684

    Rozzano, Lombardy, Italy

  • IRCCS Ospedale San Raffaele /ID# 256404

    Milan, Milano, Italy

  • P.O. Ospedale del Mare /ID# 256410

    Naples, Napoli, Italy

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Universita Cattolica /ID# 265506

    Rome, Roma, Italy

  • Puerto Rico Medical Research Center /ID# 262362

    Hato Rey, Puerto Rico, Puerto Rico

  • Hospital Universitario Vall de Hebron /ID# 255771

    Barcelona, Spain

  • Hospital Universitario Reina Sofia /ID# 255779

    Córdoba, Spain

  • Hospital General Universitario Gregorio Maranon /ID# 255772

    Madrid, Spain

  • Hospital Universitario Virgen del Rocio /ID# 255776

    Seville, Spain

  • Hospital Universitario Miguel Servet /ID# 255774

    Zaragoza, Spain

  • Hospital Universitario Marques de Valdecilla /ID# 255769

    Santander, Cantabria, Spain

  • Hospital Universitario Puerta de Hierro - Majadahonda /ID# 255778

    Majadahonda, Madrid, Spain

  • China Medical University Hospital /ID# 256764

    Taichung, Taiwan

  • Taichung Veterans General Hospital /ID# 259405

    Taichung, Taiwan

  • National Cheng Kung University Hospital /ID# 256766

    Tainan, Taiwan

  • National Taiwan University Hospital /ID# 256168

    Taipei, Taiwan

  • Taipei Veterans General Hosp /ID# 256169

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.